The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
Open accessAbstract
INTRODUCTION: Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). Durvalumab is an anti-programmed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation-positive advanced NSCLC and disease progression after EGFR-TKI therapy. METHODS: Patients were randomly assigned 1:1 to receive orally administered osimertinib (80 mg once daily) with or without durvalumab (10 mg/kg administered intravenously every 2 weeks) until progression. Treatment could continue beyond progression, providing clinical benefit continued (judged by the investigator). The amended primary objective was to assess the safety and tolerability of osimertinib plus durvalumab; efficacy was an exploratory objective. RESULTS: CAURAL recruitment was terminated early because of increased incidence of interstitial lung disease-like events in the osimertinib plus durvalumab arm from the separate phase Ib TATTON trial (NCT02143466). At termination of CAURAL recruitment, 15 patients had been randomly assigned to treatment with osimertinib and 14 to treatment with osimertinib plus durvalumab. The most common AEs were diarrhea (53% [grade ≥3 in 6% of patients]) in the osimertinib arm and rash (67% [grade ≥3 in 0 patients]) in the combination arm. One patient who had been randomized to the combination arm reported grade 2 interstitial lung disease while receiving osimertinib monotherapy (after discontinuing durvalumab therapy after one dose). The objective response rates were 80% in the osimertinib arm and 64% in the combination arm. CONCLUSION: Limited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms. The combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR-TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because of the increased risk of treatment-associated interstitial lung disease, a phase 3 clinical trial CAURAL was stopped early [193].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [193]
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
Zhang, Y., Yuan, J.-Q., Wang, K., Fu, X., Han, X., Threapleton, D. E., Yang, Z., Mao, C., & Tang, J.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.12587 · Cited by 866
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Self-citationChen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 681
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 210
Jiang, L., & Liu, J. (2022) · Oncology Letters · doi:10.3892/ol.2022.13285 · Cited by 16
Rudin, C. M., Cervantes, A. M. R., Dowlati, A., Besse, B., Ma, B., Costa, D. B., Schmid, P., Heist, R. S., Villaflor, V. M., Spahn, J. H., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101160 · Cited by 16
Ou, Y., Xia, C., Ye, C., Liu, M., Jiang, H., Zhu, Y., & Yang, D. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2398195 · Cited by 16
Immunotherapy through the Lens of Non-Small Cell Lung Cancer
Stanley, R., Flanagan, S., Reilly, D. E. O., Kearney, E., Naidoo, J., & Dowling, C. M. (2023) · Cancers · doi:10.3390/cancers15112996 · Cited by 16
Lai-Kwon, J. E., Tiu, C., Pal, A., Khurana, S., & Minchom, A. R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103225 · Cited by 16
Ahn, M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.005 · Cited by 15
Liao, D., Yu, L., Shangguan, D., Zhang, Y., Xiao, B., Liu, G., & Yang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905947 · Cited by 14
Chen, J. A., & Riess, J. W. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00750-y · Cited by 14
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Lai, G. G. Y., Yeo, J. C., Jain, A., Zhou, S., Pang, M., Alvarez, J. J. S., Sim, N. L., Tan, A. C., Suteja, L., Lim, T. W., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100416 · Cited by 13
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
Yan, D. (2023) · Biomedicines · doi:10.3390/biomedicines11112916 · Cited by 12
Li, T., Pang, X., Wang, J., Wang, S., Guo, Y., He, N., Xing, P., & Li, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.591922 · Cited by 13
Non-small-cell lung cancer: how to manage EGFR-mutated disease
Pecci, F., Cantini, L., Metro, G., Ricciuti, B., Lamberti, G., Farooqı, A. A., & Berardi, R. (2022) · Drugs in Context · doi:10.7573/dic.2022-4-1 · Cited by 12
Su, P., Tsai, J., Yang, S., Wu, Y., Tseng, Y., Chang, C., Yen, Y., Lin, C.-Y., Lin, C., Wang, C., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.014 · Cited by 13
Sun, S., Liu, C., Duan, C., Yu, S., Zhang, Q., Xu, N., Yu, B., Wu, X., Wang, J., Hu, X., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04176-x · Cited by 12
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Foffano, L., Bertoli, E., Bortolot, M., Torresan, S., Carlo, E. D., Stanzione, B., Conte, A. D., Puglisi, F., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020583 · Cited by 12
Ding, J., Ding, X., & Leng, Z. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2170879 · Cited by 11
Qi, Y. A., Maity, T. K., Gao, S., Gong, T., Bahta, M., Venugopalan, A. K., Zhang, X., & Guha, U. (2021) · Cancers · doi:10.3390/cancers13194977 · Cited by 14
Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC
Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. H. (2024) · Cancer Science · doi:10.1111/cas.16428 · Cited by 10
Hintzen, G., Dulat, H. J., & Rajkovic, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.892212 · Cited by 9
[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Guo, H., Bai, R., & Cui, J. (2020) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2020.02.05 · Cited by 10
Immunotherapy in oncogene addicted non-small cell lung cancer
McLean, L. S., Leal, J. L., Solomon, B., & John, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-772 · Cited by 11
Diao, D., Zhai, J., Yang, J., Wu, H., Jiang, J., Dong, X., Passaro, A., Aramini, B., Rao, S., & Cai, K. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-144 · Cited by 10
Self-citationImmune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
Bronte, G., Cosi, D. M., Magri, C., Frassoldati, A., Crinò, L., & Calabrò, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612622 · Cited by 10
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Zhang, D., Huang, J., Zhang, C., Guan, Y., & Guo, Q. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.06.07 · Cited by 9
Inoue, T., & Narukawa, M. (2022) · Cancer Control · doi:10.1177/10732748221140694 · Cited by 8
Ye, L., Wang, W., Li, H., Ji, Y., Le, X., & Xu, X. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241290733 · Cited by 8
Wang, L., Du, C., Jiang, B., Chen, L., & Wang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1256740 · Cited by 8
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
Burke, M., & Rashdan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720759 · Cited by 9
Stock-Martineau, S., & Shepherd, F. A. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.015 · Cited by 8
Self-citationWang, Y., Wang, Y., Yu, J., & Meng, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215947 · Cited by 8
Anaplastic Lymphoma Kinase Mutation–Positive Non–Small Cell Lung Cancer
Serritella, A. V., & Bestvina, C. M. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2019.12.001 · Cited by 9
Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?
Latif, H., & Liu, S. V. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.6 · Cited by 7
Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?
Wang, F., & Adjei, A. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.021 · Cited by 8
Zhong, W., Wu, L., Qiu, Z., Yu, W., Liu, L., Shi, H., & Wu, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1545174 · Cited by 7
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?
Lee, J., & Ahn, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000698 · Cited by 6
Self-citationPrzybylski, D. J., Bergsbaken, J., & Piccolo, J. K. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220984235 · Cited by 7
Liu, F., Zhang, X., Lu, M., Liu, C., Zhang, X., Chu, Q., Chen, Y., & Zhang, P. (2024) · Cancer Medicine · doi:10.1002/cam4.7038 · Cited by 7
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7
Immunotherapy in EGFR-mutant non-small cell lung cancer
Wang, L., Xian, X., Ke, H., & Wang, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01927-1 · Cited by 7
Chen, L., Xie, J., Zhu, M., Wang, D., Liu, H., Zhan, P., Yin, J., Ye, M., Song, Y., & Lv, T. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1092 · Cited by 6
McMahon, D. J., McLaughlin, R. A., & Naidoo, J. (2024) · Cancers · doi:10.3390/cancers16030527 · Cited by 7
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
Tian, J., Shi, Z., Zhao, L., Liu, P., Sun, X., Long, L., Zang, J., & Xiao, J. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.70037 · Cited by 5
Wei, Z., Chen, H., Wang, D., Jiang, Z., Pei, Y., Li, L.-Y., Wang, F., Jin, J., Liu, Z., Chen, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63978-y · Cited by 5
First-line combination immunotherapy for metastatic non-small cell lung cancer
Chen, Y. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000287 · Cited by 5
Harada, G., Santini, F. C., Canedo, F. S. N. A., Oliveira, L. J. D. C., Zuppani, H. B., & de Castro, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.970 · Cited by 5
Zhou, F., & Zhou, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.011 · Cited by 5
Kano, Y., Kataoka, N., Kunimatsu, Y., Tsutsumi, R., Sato, I., Tanimura, M., Nakano, T., Tanimura, K., & Takeda, T. (2022) · Medicina · doi:10.3390/medicina58060706 · Cited by 5
Maeda, A., Takase‐Minegishi, K., Kirino, Y., Hamada, N., Kunishita, Y., Yoshimi, R., Meguro, A., Namkoong, H., Horita, N., Nakajima, H., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac519 · Cited by 6
Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor—the End or Beginning?
Huang, D. D.-R., & Yang, J. C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.121 · Cited by 5
Self-citationKulendran, L., Chia, P. L., Samol, J., & Chang, A. Y. C. (2021) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2021.100132 · Cited by 4
Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis
Tanvetyanon, T., Chen, D., & Gray, J. E. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.04.019 · Cited by 4
Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
Momoi, Y., Kumagai, S., & Nishikawa, H. (2025) · International Immunology · doi:10.1093/intimm/dxaf020 · Cited by 5
EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation
Wu, Y., Yh, L., Onzere, L. E., Quan, W., Zhang, X., & Ma, J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2520962 · Cited by 6
The future of immune checkpoint combinations with tumor-targeted small molecule drugs
Sceneay, J., & Sinclair, C. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210064 · Cited by 4
Poudel, B., Desman, J. M., Aihara, G., Weidman, D. I., Tsang, A. P., Kovrizhkin, K., Pereira, T. C., Arun, S., Pradeep, T., Matin, S., et al. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100470 · Cited by 4
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
Akao, K., Oya, Y., Sato, T., Ikeda, A., Horiguchi, T., Gotô, Y., Hashimoto, N., Kondo, M., & Imaizumi, K. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00251 · Cited by 6
Dong, X., Li, R., Yao, X., Li, Y., Chen, W., An, H., Chen, J., Han, C., & Li, Y. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218203 · Cited by 3
Li, J., Yao, X., Qiu, L., Zhang, R., & Wang, G. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.101.17 · Cited by 3
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
Gullapalli, S., Remón, J., Hendriks, L. E. L., & Lopes, G. D. L., Jr. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s259308 · Cited by 3
Immunotherapy in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations
Liu, F., Yuan, X., Jiang, J., & Chu, Q. (2020) · Immunotherapy · doi:10.2217/imt-2020-0148 · Cited by 3
Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients
Wu, M., Chang, Y.-H., Chen, H., Ho, C., & Chen, H. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.04.018 · Cited by 3
Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
Loh, J., Low, J. L., Sachdeva, M., Low, P. Q. J., Wong, R. S. J., Huang, Y., Chia, P. L., & Soo, R. A. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2245140 · Cited by 3
Riess, J. W., Lara, M. S., de Rodas, M. L., Luxardi, G., Herbert, S. M., Shimoda, M., Kelly, K. L., Meerlev, A., Moore, E., Beckett, L. A., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100706 · Cited by 3
Ye, F., Yuan, X., Yu, W., Ma, Y., Mao, C., Li, X., Li, J., Dai, C., Qian, F.-H., Li, J., et al. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241273198 · Cited by 3
Pandey, S. N., Goyal, K., Rana, M., Menon, S. V., Ray, S., Kaur, M., Sharma, S., & Khan, A. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156087 · Cited by 3
Wu, X., Shi, Y., Wang, D., Liu, B., Zhang, Y., Zhang, L., Qian, F., & Zhang, W. (2026) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2026.02.005 · Cited by 2
Modern treatment of ALK-positive non-small cell lung cancer
Kharagezov, D. A., Lazutin, Y. N., Арменовна, М. Э., Milakin, A. G., Stateshny, O. N., Leyman, I. A., Gappoeva, M. A., Vitkovskaya, V. N., & Дмитриевич, И. К. (2022) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2022-3-2-5 · Cited by 3
[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
Liu, Y., & Miao, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.26 · Cited by 2
Ma, S., Hu, R., Xue, X., Qu, M., & Sun, G. (2025) · Oncology Letters · doi:10.3892/ol.2025.15170 · Cited by 2
Rui, M., Wang, Z., Fei, Z., Wu, Y., Wang, Y., Sun, L., Shang, Y., & Li, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.862640 · Cited by 2
Chu, C., Lin, C., Lin, C., Li, C., Wu, S., Tsai, J., Yang, S., Chen, C., Lin, C., Chang, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30565-4 · Cited by 2
Nishino, M., Lu, J., Hino, T., Vokes, N. I., Janne, P. A., Hatabu, H., & Johnson, B. E. (2021) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000615 · Cited by 1
Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer
Chhabra, J., Kashyap, P., Pahwa, R., Narang, R., Dureja, H., Lal, S., & Verma, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230602143605 · Cited by 1
Li, J., Zhou, X., Wu, L., Ma, J., Tan, Y., Wu, S., Zhu, J., Wang, Q., & Shi, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-13712-0 · Cited by 1
Iimura, Y., Higuchi, J., Maeda, A., Shimomura, K., Iihara, H., Fujii, H., Iwamoto, T., Saito, Y., Nomura, H., Komori, K., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03044-9 · Cited by 1
A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions
Andrews, C. N., Mukherjee, E. M., Gibson, A., Postow, M. A., Phillips, E. J., & Johnson, D. B. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.02.027 · Cited by 1
Niu, J., Jing, W., Liu, Z., Si, Y., & 刘寨东 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845547 · Cited by 1
Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies
Khoury, R., Raffoul, C., Hanna, C., Saleh, K., Shayya, A., Nahouli, M., & Ghanem, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125197 · Cited by 2
Chen, Y., Liu, Q.-P., Yang, S.-J., Ding, J., Lu, X.-Y., & Xie, H. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01855-0 · Cited by 1
[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
Chen, R., Jiang, C., Ma, L., & Zhang, S. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.37 · Cited by 1
[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].
Zhu, Y., & Dai, Z. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.44 · Cited by 1
Ou, S. I., Le, X., Nagasaka, M., Reungwetwattana, T., Ahn, M., Lim, W., Santos, E. S., Shum, E., Lau, S. C. M., Lee, J. B., et al. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s463429 · Cited by 1
Self-citationXiong, F., Shen, Y., Liu, T., Zhang, Y., & Jiang, X. (2024) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2024-005113 · Cited by 2
Basile, H. D. S., Elaidi, R., Maaradji, Z., Blons, H., BenDhiab, R., Gibault, L., & Fabre, E. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00283 · Cited by 1
Leung, S., Lim, M., & Lau, T. (2025) · Hong Kong Journal of Radiology · doi:10.12809/hkjr2417894 · Cited by 1
Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer
Wang, Y., Wang, F., Zhang, F., Niu, L., Shen, L., Zhu, L., Kang, M., Xie, X., Wang, Y., & Gao, Y. (2020) · Clinical Oncology and Research · doi:10.31487/j.cor.2020.02.08 · Cited by 1
Durvalumab for the treatment of PD-L1 non-small cell lung cancer
Naito, T., Shiraishi, H., & Fujiwara, Y. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1855075 · Cited by 1
EGFR-Directed Therapy in Lung Cancer
Kim, S. Y., Costa, D. B., Shibahara, D., Kobayashi, S. S., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009342285
Arulananda, S., & John, T. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.017 · Cited by 1
New realities of phase I clinical trials in the era of immuno-oncology: the durvalumab experience
Abdullah, S. E., Oflazoglu, E., Soria, J., & Dar, M. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz401
Louveau, B., Jouenne, F., Kaguelidou, F., Landras, A., Goldwirt, L., & Mourah, S. (2020) · Therapies · doi:10.1016/j.therap.2020.02.010
Zhang, H., Yang, X., Li, K., Wang, J., Lv, J., Li, X., Zhang, X., Qin, N., Zhang, Q., Wu, Y., et al. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.104.02
[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation].
Li, T., & Li, J. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.41
Efficacy of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR-mutationsPreprint
Sun, S., Duan, C., Yu, S., Zhang, Q., Xu, N., Hu, X., & Yu, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1618605/v1
Wójcik-Superczyńska, M., Jankowski, T., & Krawczyk, P. A. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2022.0012
Tu, H.-F., Ko, C., Lee, C., Lee, C., Lan, S.-W., Lin, H.-H., Lin, H.-Y., Ku, C., Lee, D., Chen, I., et al. (2023) · doi:10.1158/0008-5472.c.6513067
Self-citationFan, D., Dong, H., Li, A., Zhang, Y., Wang, S., Tu, Y., & Wang, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673305941240605050450
Land, S. A., Wani, R. J., Inam, N., Hewitt, H., Covizzi, P. E. M., & Rivard, T. S. (2024) · Current Oncology · doi:10.3390/curroncol31090413
Zhou, J., & Han, H. (2025) · Cancer Management and Research · doi:10.2147/cmar.s524920
Niu, J., Zhu, H., Shi, Z., Sun, Z., Jing, X., & Zd, L. (2026) · Scientific Reports · doi:10.1038/s41598-026-54690-y
Metadata
- Authors
- Yang, J. C.-H., Shepherd, F. A., Kim, D.-W., Lee, G.-W., Lee, J. S., Chang, G.-C., Lee, S. S., Wei, Y.-F., Lee, Y. G., Laus, G., Collins, B., Pisetzky, F., & Horn, L.
- Affiliations
- National Taiwan University Hospital (TW)
- University of Toronto (CA)
- Seoul National University (KR)
- Gyeongsang National University (KR)
- Taichung Veterans General Hospital (TW)
- Inje University (KR)
- E-Da Hospital (TW)
- Kangbuk Samsung Hospital (KR)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Netherlands) (NL)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 14
- Issue
- 5
- Pages
- 933-939
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2912107322
- Cited by
- 210
- References
- 17
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 39 · 2021: 42 · 2020: 27 · 2019: 13
- FWCI
- 22.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Meso Scale Diagnostics
- Takeda Pharmaceuticals North America
- AstraZeneca
- EMD Serono (NCT02454933)
- Bayer
- Celgene
- Eli Lilly and Company
- Daiichi Sankyo Company
- AbbVie
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Astellas Pharma Canada
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- osimertinib, durvalumab, T790M mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, immune checkpoint inhibitors, interstitial lung disease, safety and tolerability, combination therapy
- MeSH terms
- Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
